# Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

> **NCT06849947** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Yeon Hee Park** · enrollment: 272 (estimated)

## Conditions studied

- Breast Cancer Metastatic

## Interventions

- **DRUG:** Ribociclib with fulvestrant
- **DRUG:** Physician's choice treatments group

## Key facts

- **NCT ID:** NCT06849947
- **Lead sponsor:** Yeon Hee Park
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2031-06-30
- **Final completion:** 2031-12-31
- **Target enrollment:** 272 (ESTIMATED)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06849947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06849947, "Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06849947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*